Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Giselle K. Perez, PhD, Fangxin Hong, PhD, Andrew M. Evens, DO,MMSc, Thomas M. Habermann, MD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Puneet S. Cheema, MD, Philip A. Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Julie E. Chang, MD, David Cella, PhD, Brad S. Kahl, MD, Lynne I. Wagner, PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-140502

Published: 2020

Journal Articles

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Lisa La, Sundar Jagannath, MD, Sikander Ailawadhi, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, James W. Hardin, PhD, Hans C. Lee, MD, Mohit Narang, MD, James L. Omel, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Lynne I. Wagner, PhD, Mazaher Dhalla, PharmD, Liang Liu, MS, Ling Yang, MS, Prashant Joshi, MD, Rafat Abonour, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-137309

Published: 2020

Journal Articles

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Hans C. Lee, MD, Sikander Ailawadhi, MD, Cristina Gasparetto, MD, Sundar Jagannath, Robert M. Rifkin, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne I. Wagner, PhD, James L. Omel, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 3129.

https://doi.org/10.1182/blood-2019-126205

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD

Blood (2011) 118 (21): 4184.

https://doi.org/10.1182/blood.V118.21.4184.4184

Published: 2011

Journal Articles

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, MD, Fangxin Hong, PhD, Michael E Williams, M.D., Randy D. Gascoyne, MD, Lynne I Wagner, PhD, John C. Krauss, MD, Sandra J. Horning, MD

Blood (2011) 118 (21): LBA-6.

https://doi.org/10.1182/blood.V118.21.LBA-6.LBA-6

Published: 2011

NARROW

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only